Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Research & Development (2016 - 2026)

Intellia Therapeutics has reported Research & Development over the past 12 years, most recently at $80.7 million for Q1 2026.

  • Quarterly Research & Development fell 25.54% to $80.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $361.2 million through Mar 2026, down 21.97% year-over-year, with the annual reading at $388.9 million for FY2025, 16.61% down from the prior year.
  • Research & Development was $80.7 million for Q1 2026 at Intellia Therapeutics, down from $88.7 million in the prior quarter.
  • Over five years, Research & Development peaked at $133.1 million in Q1 2022 and troughed at $80.7 million in Q1 2026.
  • The 5-year median for Research & Development is $108.4 million (2025), against an average of $105.4 million.
  • Year-over-year, Research & Development skyrocketed 238.87% in 2022 and then fell 27.03% in 2023.
  • A 5-year view of Research & Development shows it stood at $100.0 million in 2022, then grew by 8.94% to $109.0 million in 2023, then rose by 7.25% to $116.9 million in 2024, then decreased by 24.15% to $88.7 million in 2025, then dropped by 8.93% to $80.7 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Research & Development are $80.7 million (Q1 2026), $88.7 million (Q4 2025), and $94.7 million (Q3 2025).